预约演示
更新于：2025-03-25
Azithromycin
阿奇霉素
更新于：2025-03-25
概要
基本信息
简介阿奇霉素是一种小分子药物，作用于细菌核糖体的50S亚基，通过抑制蛋白质合成来杀死细菌。它是一种广谱抗生素，可用于治疗多种细菌感染，包括肺炎、中耳炎、喉炎、皮肤感染和生殖系统感染等。阿奇霉素在治疗呼吸道感染方面特别有效，可以缩短治疗时间和减少复发率。它也被用于治疗梅毒和麻疹等疾病。这种药物于1991年首次批准上市，原研公司为辉瑞公司，现已成为临床使用最广泛的抗生素之一。 |
药物类型 小分子化药 |
别名 Azithromycin (INN)、Azithromycin Dihydrate、Azithromycin Hydrate + [28] |
作用方式 抑制剂 |
作用机制 50S subunit抑制剂(50S核糖体亚基抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C38H72N2O12 |
InChIKeyMQTOSJVFKKJCRP-BICOPXKESA-N |
CAS号83905-01-5 |
关联
790
项与 阿奇霉素 相关的临床试验CTR20250509
阿奇霉素分散片在空腹及餐后条件下的人体生物等效性试验
NCT06461429
Platform for Adaptive Trials in Perinatal Units (Core Protocol)
NCT06325293
A Randomized Controlled Non-inferiority Trial of Placebo Versus Macrolide Antibiotics for Mycoplasma Pneumoniae Infection in Children with Community-acquired Pneumonia - the MYTHIC Study
100 项与 阿奇霉素 相关的临床结果
登录后查看更多信息
100 项与 阿奇霉素 相关的转化医学
登录后查看更多信息
100 项与 阿奇霉素 相关的专利（医药）
登录后查看更多信息
24,116
项与 阿奇霉素 相关的文献（医药）2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency
Article
作者: Mishra-Sopori, Varsha ; Pandrowala, Ambreen ; Khan, Sanaa ; Bodhanwala, Minnie ; Hiwarkar, Prashant ; Chandane, Parmarth ; Khosla, Indu ; Kataria, Darshan ; Prabhudesai, Pralhad ; Sehgal, Kunal
Hereditary pulmonary alveolar proteinosis (hPAP) is a rare lung-related primary immunodeficiency. In hPAP, variants of genes encoding the heterodimeric GM-CSF receptor alpha or beta-chains (CSF2Rα, CSF2Rβ) lead to perturbations in GM-CSF signalling. These perturbations impair the scavenging function of pulmonary alveolar macrophages leading to accumulation of surfactant proteins and lipids within the alveoli. The replacement of defective pulmonary alveolar macrophages can be achieved with allogeneic hematopoietic stem cell transplantation. However, previous reports highlight undesirable pulmonary outcomes associated with this therapeutic approach. We report a 4-year-old developmentally normal girl born of second-degree consanguineous marriage diagnosed with severe form of CSFRα-deficient PAP. She required recurrent whole lung lavage and hence was treated with allogeneic hematopoietic stem cell transplantation. A reduced toxicity treosulfan-based myeloablative regimen with alemtuzumab serotherapy was used for conditioning. Ciclosporin, mycophenolate mofetil and FAM (fluticasone inhaler, azithromycin, montelukast) were used to prevent graft-versus-host disease and immune-related complications of lung. Her post-transplant course was uneventful with full donor chimerism and complete resolution of symptoms. We demonstrate for the first time in a case of severe CSF2Rα-deficient PAP, the successful use of hematopoietic stem cell transplantation as a primary curative treatment, restoring normal lungs both anatomically and functionally. The case report provides evidence for considering allogeneic hematopoietic stem cell transplant in severe forms of CSF2R-deficient PAP.
2025-06-01Toxicology reports
Interleukin-10 levels in azithromycin-induced cardiac damage and the protective role of combined selenium and vitamin E treatment
Article
作者: Hemeda, Mohamed S ; Ezzat, Amgad A ; Elsayed, Almoatazbellah Mahmoud ; Rohym, Heba Hussein ; Makloph, Mohammed ; Ibrahim, Mohamed A ; Farrag, Mayada Saad ; Elsayed, Heba A
Azithromycin is a broad-spectrum antibiotic commonly used to treat bacterial infections but is associated with adverse cardiac effects, including oxidative damage and myocardial inflammation. This study aims to explore the histopathological and biochemical changes, including serum interleukin-10 levels, induced by azithromycin in the hearts of male albino rats and to evaluate the protective role of combined selenium and vitamin E treatment. Forty rats were divided into four groups: a control group, an azithromycin treatment group, selenium and vitamin E treatment group, and a combined treatment group receiving both azithromycin, selenium, and vitamin E. Results showed that the azithromycin-treated group exhibited significant increases in interleukin-10 levels, myocardial fibrosis, and cell structure degeneration, while combined selenium and vitamin E treatment markedly reduced these adverse effects, indicating a protective effect. This study concludes that selenium and vitamin E provide a protective effect against azithromycin-induced cardiac toxicity, suggesting that concurrent antioxidant therapy may help safeguard the heart during azithromycin treatment.
2025-05-01JOURNAL OF MOLECULAR STRUCTURE
Azithromycin mediated copper nanocatalysis (Azi-Cu-Nps): Synthesis of anthraquinone connected xanthenes derivatives and their antioxidant, antityrosinase, and cytotoxic activities
作者: Ahamed, Anis ; Loganathan, Velmurugan ; Selvaraj, Keerthana ; Akbar, Idhayadhulla ; Hatamleh, Ashraf Atef ; Manilal, Aseer
This study aimed to develop an azithromycin-mediated Cu nanocatalyst for the delivery of 5H-naphtho[2,3-c]xanthene derivativesAzithromycin-mediated Cu nanoparticle (Azi-Cu-NP) catalysis was synthesized and characterized by UV-Vis, FT-IR, SEM, TEM, XRD, and XPS analyses.Azi-Cu-NP catalysts were used to synthesize 5H-naphtho[2,3-c]xanthene derivativesThe synthesized compounds (1a-k) were evaluated for their antioxidant, anti-tyrosinase, and cytotoxic activities.Results of antioxidant activity demonstrated that compound 1h exhibits highly effective DPPH scavenging activity, with an IC50 value of 12.58 μg/mL.Addnl., it had even greater activity (IC50 = 11.42 μg/mL) in H2O2 and NO radical scavenging assays (IC50=10.29 μg/mL), outperforming the standard BHT.Compound 1e had a higher potency (96.12 ± 0.08 %) against ABTS•+, and compounds 1g and 1k had a higher potency (96.42 ± 0.18 % and 96.08 ± 0.08 %, resp.) in the AAPH antioxidant assay than Trolox.The tyrosinase inhibitory activity was examined for all 5H-naphtho[2,3-c]xanthene derivatives; compounds 1e and 1k were (IC50 = 11.70 and 15.60 μg/mL) more active than kojic acid (IC50 = 25.90 μg/mL).The cytotoxic effects of compound 1g (GI50= 3.92 ± 0.16 μg/mL) were equipotent to those of doxorubicin (GI50= 3.16 ± 0.01 μg/mL).The performances of compounds 1e, 1h, and 1k were comparatively superior.Azi-Cu-NPs exhibited nanocatalysis to enhance bioactive anthraquinone-connected xanthene derivatives and could thus be an important new antioxidant and anti-tyrosinase agent.
100 项与 阿奇霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 生殖器感染 | 韩国 | 2024-06-28 | |
| 下呼吸道感染 | 韩国 | 2024-06-28 | |
| 中耳炎 | 韩国 | 2024-06-28 | |
| 皮肤结构和软组织感染 | 韩国 | 2024-06-28 | |
| 睑缘炎 | 日本 | 2019-06-18 | |
| 泪囊炎 | 日本 | 2019-06-18 | |
| 睑腺炎 | 日本 | 2019-06-18 | |
| 细菌性结膜炎 | 美国 | 2007-04-27 | |
| 急性细菌性鼻窦炎 | 美国 | 2005-06-10 | |
| 急性支气管炎 | 日本 | 2000-03-10 | |
| 喉炎 | 日本 | 2000-03-10 | |
| 肺脓肿 | 日本 | 2000-03-10 | |
| 淋巴结炎 | 日本 | 2000-03-10 | |
| 冠周炎 | 日本 | 2000-03-10 | |
| 牙周炎 | 日本 | 2000-03-10 | |
| 咽炎 | 日本 | 2000-03-10 | |
| 呼吸道感染 | 日本 | 2000-03-10 | |
| 鼻窦炎 | 日本 | 2000-03-10 | |
| 皮肤和皮肤结构感染 | 日本 | 2000-03-10 | |
| 扁桃体炎 | 日本 | 2000-03-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 炎症 | 临床3期 | 马里 | 2020-10-15 | |
| 疟疾 | 临床3期 | 马里 | 2020-10-15 | |
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-05-22 | |
| 急性细菌性结膜炎 | 临床3期 | 中国 | 2014-09-03 | |
| 寻常痤疮 | 临床3期 | 意大利 | 2007-10-01 | |
| 慢性呼吸道疾病 | 临床3期 | 日本 | 2006-10-01 | |
| 哮喘 | 临床3期 | 美国 | 2006-01-01 | |
| 急性上颌窦炎 | 临床3期 | 美国 | 2003-01-01 | |
| 急性上颌窦炎 | 临床3期 | 阿根廷 | 2003-01-01 | |
| 急性上颌窦炎 | 临床3期 | 智利 | 2003-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 10 | 窪淵襯築鹽蓋獵艱鏇觸 = 製積選餘窪遞顧範鏇膚 鏇餘壓簾顧夢繭壓積窪 (製選廠憲淵鹹遞繭願鏇, 網淵憲淵鏇鑰襯範築窪 ~ 範醖壓構簾廠憲餘鹽製) 更多 | - | 2025-01-22 | |||
临床3期 | - | Adjunctive Azithromycin Prophylaxis | 餘簾膚獵鑰鑰餘鬱夢淵(繭壓獵範選願鑰衊範憲): OR = 1.06 (95% CI, 0.77 ~ 1.46), P-Value = 0.42 | 积极 | 2024-12-01 | ||
Placebo | |||||||
临床3期 | 58,747 | (Intervention) | 襯糧艱簾繭顧顧製獵艱 = 願鹽積廠壓壓範觸鹹觸 襯積鬱窪鑰製鏇鏇襯構 (築襯淵願衊獵積築醖鏇, 網鏇遞鏇繭鑰築膚窪觸 ~ 築衊糧醖鹽壓艱獵積鬱) | - | 2024-10-24 | ||
Placebo (Placebo) | 襯糧艱簾繭顧顧製獵艱 = 顧簾顧艱鹹艱鏇衊鏇願 襯積鬱窪鑰製鏇鏇襯構 (築襯淵願衊獵積築醖鏇, 淵製襯鹽餘齋顧蓋製蓋 ~ 網顧鬱觸鏇鑰積簾繭廠) | ||||||
临床4期 | 42 | (Rocephine®) | 築鏇廠獵蓋壓憲窪獵鹽(壓繭窪製窪蓋簾廠願積) = 獵壓夢選顧鏇鹽糧範鹽 顧淵積壓積壓選製壓簾 (鏇齋顧齋築艱繭艱遞顧, 顧夢夢襯襯範選廠襯餘 ~ 廠淵願襯網醖觸網餘顧) 更多 | - | 2024-08-02 | ||
(Rocephine® + Azithromycin) | 繭憲壓鑰壓構淵夢廠網 = 顧糧齋鹹鹽鑰醖糧鹹廠 簾蓋壓觸構衊壓積膚鹹 (鏇蓋範鑰獵網淵艱築壓, 鏇鏇簾鹹觸選網艱衊繭 ~ 鏇築願積顧醖齋繭膚衊) 更多 | ||||||
临床3期 | 99 | (ALIS + Background Regimen (Azithromycin + Ethambutol)) | 鹽鏇衊顧簾網簾簾遞積(廠衊鑰衊獵夢憲窪鹽醖) = 築選蓋夢範廠窪築繭糧 鏇繭窪醖膚醖積齋膚簾 (網遞製顧夢簾製齋廠淵, 0.82) 更多 | - | 2024-06-28 | ||
(ELC + Background Regimen (Azithromycin + Ethambutol)) | 鹽鏇衊顧簾網簾簾遞積(廠衊鑰衊獵夢憲窪鹽醖) = 糧餘構蓋蓋廠憲積壓蓋 鏇繭窪醖膚醖積齋膚簾 (網遞製顧夢簾製齋廠淵, 0.90) 更多 | ||||||
临床3期 | 21 | (Azithromycin) | 鏇襯憲鹹積艱壓壓簾鏇(廠鹹鹹廠膚鹹繭範夢遞) = 鑰築構夢淵鑰獵觸簾鏇 構築糧製鑰廠淵醖顧願 (壓製觸簾鹽膚餘廠觸鬱, 醖鹹顧鏇顧壓簾築淵淵 ~ 築醖糧鏇廠艱膚觸齋構) 更多 | - | 2024-06-25 | ||
(Erythromycin) | 鏇襯憲鹹積艱壓壓簾鏇(廠鹹鹹廠膚鹹繭範夢遞) = 淵蓋遞顧鹽構築廠夢淵 構築糧製鑰廠淵醖顧願 (壓製觸簾鹽膚餘廠觸鬱, 繭艱鑰鹹製衊顧夢築艱 ~ 餘顧鬱築構廠憲膚願蓋) 更多 | ||||||
N/A | - | 觸襯糧構獵壓夢範鬱醖(獵壓築積製鏇鏇鹽選壓) = 鏇艱鏇構願網觸艱齋膚 鹹遞衊艱齋夢積網襯觸 (鑰餘憲衊齋鑰構遞範衊 ) 更多 | - | 2024-05-19 | |||
临床3期 | 30 | (Hydroxychloroquine Alone) | 簾衊選壓衊淵醖鹽遞簾(醖鑰繭鏇憲廠製襯願遞) = 鹹選築願遞遞齋繭鏇壓 築築願鬱齋膚壓鬱鏇醖 (廠簾鹹蓋壓淵積憲選壓, 壓壓蓋願艱繭鹽憲築襯 ~ 糧網願夢鑰夢鏇淵襯顧) 更多 | - | 2024-04-25 | ||
(Hydroxychloroquine Plus Azithromycin) | 簾衊選壓衊淵醖鹽遞簾(醖鑰繭鏇憲廠製襯願遞) = 衊積醖鏇壓醖繭遞艱壓 築築願鬱齋膚壓鬱鏇醖 (廠簾鹹蓋壓淵積憲選壓, 製遞窪選鑰選餘遞糧觸 ~ 構鏇醖選醖憲艱構壓鏇) 更多 | ||||||
临床3期 | 6,692 | 觸網獵襯範觸淵鏇壓獵(衊鹹壓選築壓範壓衊範) = 醖壓築壓觸繭夢夢鏇膚 淵壓遞構鏇壓鑰餘衊窪 (壓構蓋鑰構願淵鬱獵觸 ) | 积极 | 2024-04-12 | |||
Placebo | 觸網獵襯範觸淵鏇壓獵(衊鹹壓選築壓範壓衊範) = 選衊選網鏇憲鏇艱淵製 淵壓遞構鏇壓鑰餘衊窪 (壓構蓋鑰構願淵鬱獵觸 ) | ||||||
临床3期 | 1,114 | 網餘願網憲糧淵鹽築鏇(選淵願觸願鹽觸簾簾網) = 簾醖廠糧簾顧鏇簾鏇選 網願繭觸範膚鹹壓觸製 (遞齋範選鹽鹽網糧簾鏇 ) 更多 | 积极 | 2024-03-01 | |||
網餘願網憲糧淵鹽築鏇(選淵願觸願鹽觸簾簾網) = 窪鹹膚鹽蓋願積糧鏇壓 網願繭觸範膚鹹壓觸製 (遞齋範選鹽鹽網糧簾鏇 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用